Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Continuous versus intermittent intravenous antipseudomonal beta-lactam infusion for cystic fibrosis pulmonary exacerbation
ACTRN12612000945820Phase 4Recruiting
- Sponsor
- Dr Anton Peleg
- Start
- Nov 2012
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ceftazidime, ticarcillin plus clavulanic acid, meropenem, cefepime and piperacillin + tazobactam in cystic fibrosis (CF) and Pseudomonas aeruginosa pulmonary infection (2 arms), sponsored by Dr Anton Peleg. Primary endpoint: Change in Cystic Fibrosis Questionnaire-Revised respiratory symptom score. Started Nov 2012; status: recruiting.
02
Drugs
ceftazidimeticarcillin plus clavulanic acidmeropenemcefepimepiperacillin + tazobactam
03
Conditions
cystic fibrosis (CF)Pseudomonas aeruginosa pulmonary infection
Beyond the preview
Go deeper on ACTRN12612000945820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000945820.